Human PilotPubMed ID: 8148713·1994

Systemic lupus erythematosus treatment with thymosin alpha-1

Benson CA, Crowe LM, Campbell GD Jr.

Lupus, 1994 · n = 18

Key finding

Modest benefits in 33% of patients; improved T-cell function but variable clinical response; difficult to disentangle from concurrent corticosteroid therapy.

Summary

Preliminary study of thymosin alpha-1 in lupus patients, examining immunological markers and clinical response.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

Thymosin Alpha-1L4

A naturally occurring thymic peptide approved internationally for immune modulation, with extensive clinical data in hepatitis and cancer immunotherapy.

More research on Thymosin Alpha-1

COVID-19 immunotherapy: thymosin alpha-1 efficacy in severe disease

Cytokine · 2021 · Human RCT

Combination immunotherapy: thymosin alpha-1 with checkpoint inhibitors in cancer

Journal for ImmunoTherapy of Cancer · 2020 · Human Pilot

Thymalfasin: clinical pharmacology and antiviral applications

BioDrugs · 2010 · Review

Thymosin alpha-1 safety profile: adverse events across 50+ clinical trials

Current Aging Science · 2010 · Review

Thymosin alpha-1 and thymic regeneration in aging

Nature Immunology · 2009 · Animal Study